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Introduction 
The opioid receptors (ORs) are known to be distributed widely in the central nervous 
system (CNS) and in peripheral sensory and autonomic nerves. Activation of ORs by 
endogenous and exogenous ligands results in a multitude of physiological functions and 
behaviors, e.g. pain and analgesia, stress and social status, tolerance and dependence, 
learning and memory, eating and drinking, and many more [1]. Due to this widespread 
pharmacological profile of ORs, opioid peptides are becoming key players in the 
pharmaceutical industry, more specifically in research and development of pain modulating 
agents. Among the opioid receptor subtypes, the µ-opioid receptor subtype is the main 
target due to its essential contribution to control pain (i.e. narcotic analgesics used in clinic 
are all agonists of the µ-opioid receptor subtype) [2]. For analgesics to target ORs in the 
CNS and exert medical activity, opioid peptides should penetrate the blood–brain barrier 
(BBB), with limited efflux behavior, have a favorable receptor-subtype selectivity and 
sufficient metabolic stability.  
 
Results and Discussion 
The opioid receptor-subtype selectivity can be assessed not only by the classic radioligand 
binding methods, but also by novel techniques such as SAW (surface acoustic wave) 
measuring the binding kinetics. Pharmacokinetics include metabolic stability, brain influx 
and efflux characteristics, as well as brain capillary retention. Metabolic stability is 
evaluated i.a. by in vitro kinetic studies using different target tissues. Using in vivo mouse 
models, the influx transfer constant from serum into mouse brain is determined by multiple 
time regression, while the efflux kinetics are investigated with the intra-cerebroventricular 
injection technique. Furthermore, the brain parenchyma/capillary distribution is evaluated 
by the capillary depletion method. Finally, the in vivo antinociceptive activity can be 
quantified in a mouse model. 
During these initial research and discovery phase, the peptide quality and its stability 
characteristics are often neglected, possibly leading to misinterpretation of biological 
results, and thus are important factors to avoid false functionality conclusions [3]. 
Results evaluating the requested and labeled (supplier’s certificate of analysis) versus the 
experimentally determined quality of 46 peptides from one supplier were problematic. The 
quality of more than 30% of the evaluated peptides was below  90% compared to the 
requested 95% purity. This confirms a previous study where the quality of one peptide from 
different suppliers was also found to be problematic [7]. Moreover, these impurities do 
influence the functionality, as demonstrated by the observed baseline contraction of guinea 
pig ileum longitudinal smooth muscle in a tissue organ bath test which was due to the 
impurities and not to the peptide INSL6[151-161] itself [3].  
The stability of peptides during ex vivo experiments was also evaluated, demonstrating that 
some remained stable but others were chemically and/or physically (adsorption to 
tissue/glass) unstable and thus unable to exert their full functionality. 
In order to have a good antinociceptive activity, the BBB characteristics of opioid peptides 
should be favorable. Information about the BBB behavior of peptides, including the 
opioids, is scattered throughout the literature, with a wide variety of different study 
protocols being used. Therefore, the currently available BBB-data are collated in the 
database Brainpeps, which can i.a. be used for QSPR analyses [4]. Moreover, the CNS-
functional drugability of a set of opioid peptides was comparatively scored using a 
Derringer’s desirability function combining the different drugability requirements into a 
single figure-of-merit [5]. The overall in vivo antinociceptive effect of these opioid peptides 
was also investigated using a tail-flick mouse model [6]: the obtained in vivo results 
correlated well with the ranking from the desirability criterion. 
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